Literature DB >> 6180187

Secretion into and elimination from blood circulation of prostate specific acid phosphatase, measured by radioimmunoassay.

P Vihko, F H Schroeder, O Lukkarinen, R Vihko.   

Abstract

The concentration of prostate specific acid phosphatase (PAP) was significantly higher in serum specimens from prostatic venous plexus blood than from peripheral venous blood in 6 patients operated upon because of benign prostatic hypertrophy. This suggests that normally circulating PAP is secreted via the prostatic venous plexus. We also investigated the disappearance of PAP from the circulation after total prostatectomy and staging pelvic lymphadenectomies in 5 patients with nonmetastazing prostatic cancer and in 1 patient with bladder cancer. During the postmaximum period, serum PAP concentrations declined, following 2-exponential curves, the 1st mean half life of elimination being 1.2 hours (range 0.5--2.5 hours). It is possible that PAP released from the prostate during the operation was eliminated during the 1st period. The 2nd half life was found to be remarkably long (mean = 281 hours), and it may represent PAP bound by serum protein(s).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180187     DOI: 10.1016/s0022-5347(17)52818-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Radiolabelling of monoclonal antibodies: optimization of conjugation of DTPA to F(ab')2-fragments and a novel measurement of the degree of conjugation using Eu(III)-labelling.

Authors:  M Hartikka; P Vihko; M Södervall; L Hakalahti; P Torniainen; R Vihko
Journal:  Eur J Nucl Med       Date:  1989

Review 2.  Pain-relieving prospects for adenosine receptors and ectonucleotidases.

Authors:  Mark J Zylka
Journal:  Trends Mol Med       Date:  2011-01-13       Impact factor: 11.951

3.  Biodistribution in normal mice of an 111In-labelled prostatic acid phosphatase-specific antibody and its F(ab')2 fragments derivatized site-specifically or via bicyclic diethylenetriaminepentaacetic acid anhydride.

Authors:  M Perälä; P Vihko; M Södervall; J Heikkilä; R Vihko
Journal:  Eur J Nucl Med       Date:  1990

4.  Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.

Authors:  M Perälä-Heape; P Vihko; A Laine; J Heikkilä; R Vihko
Journal:  Eur J Nucl Med       Date:  1991

5.  Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine.

Authors:  Mark J Zylka; Nathaniel A Sowa; Bonnie Taylor-Blake; Margaret A Twomey; Annakaisa Herrala; Vootele Voikar; Pirkko Vihko
Journal:  Neuron       Date:  2008-10-09       Impact factor: 17.173

6.  Serum half life of prostatic acid phosphatase.

Authors:  J Wadström; M Wenk; P Huber
Journal:  Urol Res       Date:  1985

7.  PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain.

Authors:  Julie K Hurt; Mark J Zylka
Journal:  Mol Pain       Date:  2012-04-23       Impact factor: 3.395

8.  Prostatic acid phosphatase is expressed in peptidergic and nonpeptidergic nociceptive neurons of mice and rats.

Authors:  Bonnie Taylor-Blake; Mark J Zylka
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.